MedXCell announces appointment of M. Laurent Dassault and M. Philippe Archinard as new board members

February 8, 2024
• MedXCell to appoint Laurent Dassault et Philippe Archinard as two new members of its Board of Directors • The two new members join Anh Nguyen, Chairman, Laurent Zbinden, Vice-Chairman, Andrew Galazka, MD, and Gabriel Baertschi.

Montreux, February 8, 2024 – MedXCell, a Swiss biotech venture builder led by entrepreneurs and backed by private investors, proudly welcomes M. Laurent Dassault and M. Philippe Archinard to its Board of Directors (the “Board”). Their esteemed leadership will position MedXCell for its upcoming phase of growth.

Laurent Dassault is a distinguished business leader with extensive experience in the financial and industrial sector, currently serving as a Director of GIMD (Groupe Industriel Marcel Dassault). After a successful career in the banking sector, Mr. Dassault joined the Dassault Group, overseeing the diversification of the group’s activities and investments. Mr. Dassault currently exercises multiple strategic mandates across various sectors.

Philippe Archinard, PhD, is a seasoned executive with a successful track record in biotechnology. He currently serves as Deputy CEO, Technological Innovation, and Scientific Partnerships at Institut Mérieux. From 2004 to 2020, Dr. Archinard served as the CEO of Transgene, a leading immunotherapy company. Prior to that, he held key positions as President of bioMérieux Inc. (USA), EVP of bioMérieux SA, and CEO of Innogenetics BV. He holds a PhD in biochemistry.

Laurent Zbinden, CEO, and Vice-Chairman expressed his pleasure, stating: “Mr. Dassault and M. Archinard will undoubtedly propel our company into its next developmental stage. We take pride in their addition to our Board. Their support in our venture builder showcases the credibility of our model and how successful we can be in rapidly translating science into products.

The newly reinforced Board, chaired by Anh Nguyen, and composed of Laurent Zbinden, Laurent Dassault, Philippe Archinard, Andrew Galazka and Gabriel Baertschi, is set to drive MedXCell forward with collective expertise and vision.


MedXCell is a Swiss biotech venture builder led by entrepreneurs and backed by private investors. Its operating model involves co-designing early-stage projects with academic institutions, followed by the creation of independent business ventures centered around the most commercially-viable ideas. MedXCell subsequently finances and manages the operations of these ventures before integrating co-investors for later-stage development. Currently, MedXCell focuses on the further development of its portfolio, which includes two robust technological platforms, CYTEA BIO and BIORESPX, both of which have progressed to the non-clinical proof of concept (POC) stage.